Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
CURATE.AI Optimized Modulation for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Other: CURATE.AI-Guided dosage modulation
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 20
- Registration Number
- NCT03759093
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Expanded Access for CC-2001
- Conditions
- DermatologicOther
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Celgene
- Registration Number
- NCT03723083
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Blood Diseases Clinic
- Target Recruit Count
- 654
- Registration Number
- NCT03651102
- Locations
- 🇵🇰
Blood Diseases Clinic, Peshawar, Khyber Pakhtukhwa, Pakistan
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT03608501
- Locations
- 🇧🇷
Instituto COI de Educacao e Pesquisa, Rio de Janeiro, RJ, Brazil
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
🇧🇷Universidade Estadual de Campinas UNICAMP - HEMOCENTRO, Campinas, SP, Brazil
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Yunpeng Liu
- Target Recruit Count
- 880
- Registration Number
- NCT03601871
- Locations
- 🇨🇳
Fushun Central Hospital, Fushun, Liaoning, China
🇨🇳cancer hospital of Haerbin Medical University, Haerbin, Heilongjiang, China
🇨🇳Siping City Cancer Hospital, Siping, Jilin, China
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT03341494
- Locations
- 🇨🇳
Fujian Cancer Hospital Radiation Oncology Department, Fuzhou, Fujian, China
🇨🇳Fujian cancer hospital, Fuzhou, Fujian, China
Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 162
- Registration Number
- NCT03318835
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- IRCCS Burlo Garofolo
- Target Recruit Count
- 9
- Registration Number
- NCT03221166
- Locations
- 🇮🇹
Gastroenterologia e Nutrizione Pediatrica, Azienda Ospedaliero Universitaria Meyer, Firenze, Toscana, Italy
🇮🇹IRCCS Burlo Garofolo, Trieste, Friuli Venezia Giulia, Italy
🇮🇹Fondazione MBBM , Azienda Ospedaliera San Gerardo - Università Milano Bicocca, Monza, Lombardia, Italy
The Therapeutic Effect of Thalidomide in RI
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2019-11-22
- Target Recruit Count
- 58
- Registration Number
- NCT03208413
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Guangzhou Huiai Hospital, Guanzhou, Guangdong, China
🇨🇳Cancer canter of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
- Conditions
- Extrapancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT03204032
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.